Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04430517 · ClinicalTrials.gov registry record · Early Phase 1
Effects of Nicotinamide Riboside on Bioenergetics and Oxidative Stress in Mild Cognitive Impairment/Alzheimer's Dementia
A Early Phase 1 study of Mild Cognitive Impairment and Mild Alzheimer Disease, sponsored by Mclean Hospital.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT04430517: Recruiting Early Phase 1 study of Mild Cognitive Impairment and Mild Alzheimer Disease, sponsored by Mclean Hospital.
NCT04430517 is a Early Phase 1 study of Mild Cognitive Impairment and Mild Alzheimer Disease that is actively recruiting participants, run by Mclean Hospital. The registered enrollment target is 50 participants, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04430517, a Early Phase 1 study of Mild Cognitive Impairment and Mild Alzheimer Disease, is actively recruiting participants, sponsored by Mclean Hospital.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary aim of this study is to investigate the effects of exogenously administered nicotinamide riboside (NR) on brain energy metabolism, oxidative stress, and cognitive function in individuals with mild cognitive impairment (MCI) and mild Alzheimer's dementia (AD).
Primary Outcome
Changes in brain NAD+ levels
Conditions Studied
Interventions
- DRUG Nicotinamide riboside
Study Locations (1)
Massachusetts
- McLean Hospital - Belmont
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-03-02 |
| Est. Completion | 2026-03-01 |
| Phase | Early Phase 1 |
What NCT04430517 shows while recruiting
NCT04430517 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Mild Cognitive Impairment appearing as the primary indexed condition, and to 1 intervention - of which Nicotinamide riboside is the first listed.
NCT04430517 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04430517 about?
NCT04430517 is a clinical study titled "Effects of Nicotinamide Riboside on Bioenergetics and Oxidative Stress in Mild Cognitive Impairment/Alzheimer's Dementia". The primary aim of this study is to investigate the effects of exogenously administered nicotinamide riboside (NR) on brain energy metabolism, oxidative stress, and cognitive function in individuals with mild cognitive impairment (MCI) and mild Alzheimer's dementia (AD).
What is the current status of trial NCT04430517?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 50 participants. The study started on 2022-03-02. Estimated completion is 2026-03-01.
What conditions does trial NCT04430517 study?
This clinical trial studies the following conditions: Mild Cognitive Impairment, Mild Alzheimer Disease.
What interventions are being tested in trial NCT04430517?
The interventions under investigation include: Nicotinamide riboside (DRUG).
Who is sponsoring clinical trial NCT04430517?
This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04430517 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mild Cognitive Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04430517's enrollment target sits among peer trials
50 140th of 205 higher than 62 of 205 other Mild Cognitive Impairment trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mild Cognitive Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
RECRUITING · Early Phase 1
-
Time-in-bed Restriction in Older Adults With Sleep Difficulties With and Without Risk for Alzheimer's Disease
RECRUITING · Early Phase 1
-
Transcranial Magnetic Stimulation Treatment for Alzheimer's Disease
RECRUITING · Early Phase 1
-
Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease
ACTIVE NOT RECRUITING · Early Phase 1
-
Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy
ACTIVE NOT RECRUITING · Early Phase 1
-
Glutathione in Mild Cognitive Impairment
ACTIVE NOT RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI